Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE-X for initially unresectable hepatocellular carcinoma
jRCTs071250043Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tremelimumab and durvalumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoint: Incidence of postoperative complications of Clavien-Dindo grade 3 or higher. Started Sep 2025; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs071250043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071250043.